Breaking News

Medpharm Announces Merger with Tergus Pharma

The combined organization will establish an end-to-end CDMO with robust scientific, clinical trial manufacturing and commercial production capabilities.

Author Image

By: Charlie Sternberg

Associate Editor

MedPharm, a global topical and transdermal CDMO and an Ampersand Capital Partners portfolio company, is merging with Tergus Pharma, a Great Point Partners portfolio company. The combined organization will operate under the MedPharm name, establishing an end-to-end CDMO with robust scientific, clinical trial manufacturing and commercial production capabilities. Tergus lead investor Great Point Partners will retain a significant minority ownership stake in the newly combined MedPharm, whil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters